Hu Zhang1, Jian Qi1, Ya-Qiong Wu1, Ping Zhang1, Jun Jiang1, Qi-Xian Wang1, You-Qing Zhu1. 1. Hu Zhang, Jian Qi, Qi-Xian Wang, You-Qing Zhu, Department of Gastroenterology and Clinical Centre of Intestinal and Colorectal Diseases of Hubei Province, Zhongnan Hospital of Wuhan University, Wuhan 430071, Hubei Province, China.
Abstract
AIM: To evaluate the accuracy of methylation of genes in stool samples for diagnosing colorectal tumours. METHODS: Electronic databases including PubMed, Web of Science, Chinese Journals Full-Text Database and Wanfang Journals Full-Text Database were searched to find relevant original articles about methylated genes to be used in diagnosing colorectal tumours. A quality assessment of diagnostic accuracy studies tool (QADAS) was used to evaluate the quality of the included articles, and the Meta-disc 1.4 and SPSS 13.0 software programs were used for data analysis. RESULTS: Thirty-seven articles met the inclusion criteria, and 4484 patients were included. The sensitivity and specificity for the detection of colorectal cancer (CRC) were 73% (95%CI: 71%-75%) and 92% (95%CI: 90%-93%), respectively. For adenoma, the sensitivity and specificity were 51% (95%CI: 47%-54%) and 92% (95%CI: 90%-93%), respectively. Pooled diagnostic performance of SFRP2 methylation for CRC provided the following results: the sensitivity was 79% (95%CI: 75%-82%), the specificity was 93% (95%CI: 90%-96%), the diagnostic OR was 47.57 (95%CI: 20.08-112.72), the area under the curve was 0.9565. Additionally, the results of accuracy of SFRP2 methylation for detecting colorectal adenomas were as follows: sensitivity was 43% (95%CI: 38%-49%), specificity was 94% (95%CI: 91%-97%), the diagnostic OR was 11.06 (95%CI: 5.77-21.18), and the area under the curve was 0.9563. CONCLUSION: Stool-based DNA testing may be useful for noninvasively diagnosing colorectal tumours and SFRP2 methylation is a promising marker that has great potential in early CRC diagnosis.
AIM: To evaluate the accuracy of methylation of genes in stool samples for diagnosing colorectal tumours. METHODS: Electronic databases including PubMed, Web of Science, Chinese Journals Full-Text Database and Wanfang Journals Full-Text Database were searched to find relevant original articles about methylated genes to be used in diagnosing colorectal tumours. A quality assessment of diagnostic accuracy studies tool (QADAS) was used to evaluate the quality of the included articles, and the Meta-disc 1.4 and SPSS 13.0 software programs were used for data analysis. RESULTS: Thirty-seven articles met the inclusion criteria, and 4484 patients were included. The sensitivity and specificity for the detection of colorectal cancer (CRC) were 73% (95%CI: 71%-75%) and 92% (95%CI: 90%-93%), respectively. For adenoma, the sensitivity and specificity were 51% (95%CI: 47%-54%) and 92% (95%CI: 90%-93%), respectively. Pooled diagnostic performance of SFRP2 methylation for CRC provided the following results: the sensitivity was 79% (95%CI: 75%-82%), the specificity was 93% (95%CI: 90%-96%), the diagnostic OR was 47.57 (95%CI: 20.08-112.72), the area under the curve was 0.9565. Additionally, the results of accuracy of SFRP2 methylation for detecting colorectal adenomas were as follows: sensitivity was 43% (95%CI: 38%-49%), specificity was 94% (95%CI: 91%-97%), the diagnostic OR was 11.06 (95%CI: 5.77-21.18), and the area under the curve was 0.9563. CONCLUSION: Stool-based DNA testing may be useful for noninvasively diagnosing colorectal tumours and SFRP2 methylation is a promising marker that has great potential in early CRC diagnosis.
Authors: Hannes M Müller; Michael Oberwalder; Heidi Fiegl; Maria Morandell; Georg Goebel; Matthias Zitt; Markus Mühlthaler; Dietmar Ofner; Raimund Margreiter; Martin Widschwendter Journal: Lancet Date: 2004-04-17 Impact factor: 79.321
Authors: Thomas F Imperiale; David F Ransohoff; Steven H Itzkowitz; Barry A Turnbull; Michael E Ross Journal: N Engl J Med Date: 2004-12-23 Impact factor: 91.245
Authors: David A Ahlquist; William R Taylor; Douglas W Mahoney; Hongzhi Zou; Michael Domanico; Stephen N Thibodeau; Lisa A Boardman; Barry M Berger; Graham P Lidgard Journal: Clin Gastroenterol Hepatol Date: 2011-10-20 Impact factor: 11.382
Authors: Linda J W Bosch; Frank A Oort; Maarten Neerincx; Carolina A J Khalid-de Bakker; Jochim S Terhaar sive Droste; Veerle Melotte; Daisy M A E Jonkers; Ad A M Masclee; Sandra Mongera; Madeleine Grooteclaes; Joost Louwagie; Wim van Criekinge; Veerle M H Coupé; Chris J Mulder; Manon van Engeland; Beatriz Carvalho; Gerrit A Meijer Journal: Cancer Prev Res (Phila) Date: 2011-12-01
Authors: F Javier Carmona; Daniel Azuara; Antonio Berenguer-Llergo; Agustin F Fernández; Sebastiano Biondo; Javier de Oca; Francisco Rodriguez-Moranta; Ramón Salazar; Alberto Villanueva; Mario F Fraga; Jordi Guardiola; Gabriel Capellá; Manel Esteller; Victor Moreno Journal: Cancer Prev Res (Phila) Date: 2013-05-21
Authors: Penny Whiting; Anne W S Rutjes; Johannes B Reitsma; Patrick M M Bossuyt; Jos Kleijnen Journal: BMC Med Res Methodol Date: 2003-11-10 Impact factor: 4.615
Authors: Hélder Almeida-Lousada; André Mestre; Sara Ramalhete; Aryeh J Price; Ramon Andrade de Mello; Ana D Marreiros; Ricardo Pires das Neves; Pedro Castelo-Branco Journal: Curr Oncol Date: 2021-11-20 Impact factor: 3.677